87 related articles for article (PubMed ID: 10626094)
1. Safety study of lazabemide (Ro19-6327), a new MAO-B inhibitor, on cardiac arrhythmias and blood pressure of patients with Parkinson's disease.
Narabayashi H; Yamaguchi T; Sugi K; Mitamura H; Mizuno Y; Nakashima M
Clin Neuropharmacol; 1999; 22(6):340-6. PubMed ID: 10626094
[TBL] [Abstract][Full Text] [Related]
2. A controlled trial of lazabemide (RO19-6327) in untreated Parkinson's disease. Parkinson Study Group.
Ann Neurol; 1993 Apr; 33(4):350-6. PubMed ID: 8489205
[TBL] [Abstract][Full Text] [Related]
3. Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group.
Ann Neurol; 1996 Jul; 40(1):99-107. PubMed ID: 8687199
[TBL] [Abstract][Full Text] [Related]
4. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
deMarcaida JA; Schwid SR; White WB; Blindauer K; Fahn S; Kieburtz K; Stern M; Shoulson I; ;
Mov Disord; 2006 Oct; 21(10):1716-21. PubMed ID: 16856145
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
6. A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease. Parkinson Study Group.
Arch Neurol; 1994 Apr; 51(4):342-7. PubMed ID: 8155011
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
Talati R; Reinhart K; Baker W; White CM; Coleman CI
Parkinsonism Relat Disord; 2009 Aug; 15(7):500-5. PubMed ID: 19167259
[TBL] [Abstract][Full Text] [Related]
8. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Parkinson Study Group
Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
[TBL] [Abstract][Full Text] [Related]
9. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
Stern MB; Marek KL; Friedman J; Hauser RA; LeWitt PA; Tarsy D; Olanow CW
Mov Disord; 2004 Aug; 19(8):916-23. PubMed ID: 15300656
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-B inhibitor lazabemide in healthy subjects.
Dingemanse J; Wood N; Jorga K; Kettler R
Br J Clin Pharmacol; 1997 Jan; 43(1):41-7. PubMed ID: 9056051
[TBL] [Abstract][Full Text] [Related]
11. Lisuride and bromocryptine in L-Dopa stable-responder parkinsonian patients: a comparative, double-blind evaluation of cardiopressor and neurochemical effects.
Micieli G; Martignoni E; Cavallini A; Pacchetti C; Rossi F; Horowski R; Nappi G
Funct Neurol; 1996; 11(6):317-25. PubMed ID: 9074912
[TBL] [Abstract][Full Text] [Related]
12. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
13. Are current recommendations to diagnose orthostatic hypotension in Parkinson's disease satisfactory?
Jamnadas-Khoda J; Koshy S; Mathias CJ; Muthane UB; Ragothaman M; Dodaballapur SK
Mov Disord; 2009 Sep; 24(12):1747-51. PubMed ID: 19562759
[TBL] [Abstract][Full Text] [Related]
14. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors.
Bainbridge JL; Page RL; Ruscin JM
Neurol Clin; 2008 Aug; 26(3 Suppl):S85-96, vi. PubMed ID: 18774444
[TBL] [Abstract][Full Text] [Related]
15. Symptomatic anti-parkinsonian effects of monoamine oxidase-B inhibition: comparison of selegiline and lazabemide.
LeWitt PA; Segel SA; Mistura KL; Schork MA
Clin Neuropharmacol; 1993 Aug; 16(4):332-7. PubMed ID: 8374913
[TBL] [Abstract][Full Text] [Related]
16. Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation.
Berlin I; Aubin HJ; Pedarriosse AM; Rames A; Lancrenon S; Lagrue G;
Addiction; 2002 Oct; 97(10):1347-54. PubMed ID: 12359039
[TBL] [Abstract][Full Text] [Related]
17. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
18. Tyramine pharmacodynamics during combined administration of lazabemide and moclobemide.
Dingemanse J; Hussain Y; Korn A
Int J Clin Pharmacol Ther; 1996 Apr; 34(4):172-7. PubMed ID: 8861736
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose.
Pahwa R; Koller WC; Trosch RM; Sherry JH;
J Neurol Sci; 2007 Jul; 258(1-2):137-43. PubMed ID: 17466338
[TBL] [Abstract][Full Text] [Related]
20. MAO-B inhibitor know-how: back to the pharm.
Lewitt PA
Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057
[No Abstract] [Full Text] [Related]
[Next] [New Search]
